Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (9): 1021-1024.doi: 10.3969/j.issn.1000-6621.2019.09.020
• Review Articles • Previous Articles
Zhe-wen REN,Jun CHENG,Cai-hong XU,Hui ZHANG()
Received:
2019-08-12
Online:
2019-09-10
Published:
2019-09-06
Contact:
Hui ZHANG
E-mail:zhanghui@chinacdc.cn
Zhe-wen REN,Jun CHENG,Cai-hong XU,Hui ZHANG. Progression of preventive treatment of latent tuberculosis infection in close contacts of patients with tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(9): 1021-1024. doi: 10.3969/j.issn.1000-6621.2019.09.020
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.09.020
治疗方案 | 剂量 | 疗程 | 推荐机构 |
---|---|---|---|
6~9个月INH单药 | 成人5mg/kg,儿童10mg/kg,最大剂量300mg/d | 6~9个月,每日服药 | WHO[ |
3(Rft+INH) | (1)INH:12岁及以上 15mg/kg;12岁以下,25mg/kg;最大剂量900mg/d。(2)Rft:体质量0.0~14.0kg,300mg/d;体质量14.1~25.0kg,450mg/d;体质量25.1~32.0kg,600mg/d;体质量32.1~50.0kg,750mg/d。最大剂量900mg/d | 3个月,1次/周或2次/周 | WHO[ |
4个月RFP单药 | 成人10mg/kg,儿童15mg/kg,最大剂量600mg/d | 4个月,每日服药 | WHO[ |
3(RFP+INH) | (1)INH:成人5mg/kg,儿童10mg/kg,最大剂量300mg/d。(2)RFP:成人10mg/kg,儿童15mg/kg,最大剂量600mg/d | 3个月,每日服药 | WHO[ |
[1] | Mack U, Migliori GB, Sester M , et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J, 2009,33(5):956-973. |
[2] | World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018. |
[3] | Houben RM, Dodd PJ . The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med, 2016,13(10):e1002152. |
[4] | Comstock GW, Livesay VT, Woolpert SF . The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol, 1974,99(2):131-138. |
[5] | Fox GJ, Barry SE, Britton WJ , et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2013,41(1):140-156. |
[6] | Greenaway C, Palayew M, Menzies D . Yield of casual contact investigation by the hour. Int J Tuberc Lung Dis, 2003,7(12 Suppl 3):S479-485. |
[7] | World Health Organization. Latent TB infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. |
[8] | National Tuberculosis Controllers Association, Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep, 2005,54(RR-15):1-47. |
[9] | Horwitz O, Payne PG, Wilbek E . Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ, 1966,35(4):509-526. |
[10] | Ferebee SH, Mount FW . Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis, 1962,85:490-510. |
[11] | Triasih R, Robertson CF, Duke T , et al. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clini Infect Dis, 2015,60(1):12-18. |
[12] | Zelner JL, Murray MB, Becerra MC , et al. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis. Am J Respir Crit Care Med, 2014,189(7):853-859. |
[13] | World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015. |
[14] | Wysocki AD, Villa TC, Arakawa T , et al. Latent tuberculosis infection diagnostic and treatment cascade among contacts in primary health care in a city of Sao Paulo State, Brazil: Cross-sectional study. PLoS One, 2016,11(6):e0155348. |
[15] | Okwara FN, Oyore JP, Were FN , et al. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya-a cohort study. BMC Infect Dis, 2017,17(1):623. |
[16] | Sterling TR, Villarino ME, Borisov AS , et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166. |
[17] | 张燕媚, 詹星煌 . 控制肺结核患者家庭中密切接触者感染及预防服药效果观察. 河南预防医学杂志, 2016,27(6):421-423. |
[18] | Datiko DG, Yassin MA, Theobald SJ , et al. A community-based isoniazid preventive therapy for the prevention of childhood tuberculosis in Ethiopia. Int J Tuberc Lung Dis, 2017,21(9):1002-1007. |
[19] | Sun HY, Huang YW, Huang WC , et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018,111:121-126. |
[20] | 翁丽霞, 王勇 . 学校涂阳肺结核密切接触者筛查及预防性服药效果分析. 国际流行病学传染病学杂志, 2014,41(4):258-260. |
[21] | 戴景涛, 卓玛 . 结核潜伏性感染预防性治疗效果分析. 医药前沿, 2018,8(31):219-220. |
[22] | 张子胜, 林宪和 . 涂阳肺结核患者家庭密切接触儿童感染发病及预防的研究. 中国热带医学, 2015,15(1):67-69. |
[23] | Fiske CT, Yan FX, Hirsch-Moverman Y , et al. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis, 2014,18(4):421-427. |
[24] | Wang JY, Shu CC, Lee CH , et al. Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis. J Infect, 2012,64(3):291-298. |
[25] | Centers for Disease Control and Prevention. Latent tuberculosis infection: A guide for primary health care providers. Atlanta: Centers for Disease Control and Prevention, 2010. |
[26] | Bamrah S, Brostrom R, Dorina F , et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014,18(8):912-918. |
[27] | Seddon JA, Hesseling AC, Finlayson H , et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis, 2013,57(12):1676-1684. |
[28] | European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: European Centre for Disease Prevention and Control, 2012. |
[29] | American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep, 2000,49(RR-6):1-51. |
[30] | National Institute for Health and Care Excellence. Tuberculosis. London: National Institute for Health and Care Excellence, 2016. |
[1] | Zhang Peize, Gao Qian, Deng Guofang. [18F]FDT-PET-CT technology that may bring revolutionary changes to tuberculosis clinical research [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 262-265. |
[2] | You Chengdong, Zhu Ling, Li Peibo. Research progress on serum trace elements in the development and nutritional support of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 218-223. |
[3] | Fu Ying, Xiong Yangyang, Fang Si, Li Chuanxiang, Guo Hongrong. The research progress on the relationship between serum albumin and its derivative biomarkers and chronic obstructive pulmonary disease [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 231-236. |
[4] | Li Wenhan, Yang Jing, Li Chunhua. Research progress of artificial intelligence in pulmonary tuberculosis imaging diagnosis and drug resistance prediction [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1098-1103. |
[5] | Xu Chunhua, Zhu Shiyu, Hu Yi, Yi Kehua, Song Canlei, Wang Zichun, Wu Yong, Wang Qing, Yang Qianru, Shen Xin. Analysis of screening effect of recombinant Mycobacterium tuberculosis fusion protein in screening Mycobacterium tuberculosis infection in close contacts of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 897-902. |
[6] | He Xiangrong, Chen Hua, Chen Pinru, Liang Feng, Ren Huili, Zhu Jialou, Hu Jinxing, Tan Yaoju. A case report and literature review of Mycobacterium asiaticum pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 763-769. |
[7] | Xu Wenhui, Zhang Yanqiu, Shi Jie, Sun Dingyong. Advances in biomarker research for tuberculosis diagnosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 713-721. |
[8] | Ye Xinchun, Liu Saiduo, Cheng Fang, Jiang Xiangao, Ning Hongye, Wu Zhengxing, Zhou Yueying, Qiu Chaochao, Pan Ning, Shi Jichan. Risk factors of latent tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 525-530. |
[9] | Xu Chenyi, Chen Hui, Zhong Jiyuan, Ding Xiaoyan, Yang Rui, Xu Xiangchao, Zhang Canyou, Cheng Jun, Li Tao. Investigation on the status of tuberculosis infection among household student close contacts of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 375-382. |
[10] | Fan Xiaolei, Maiwulajiang·Yimamu , Peng Xiaowang, Hu Pengyuan, Wang Yanjie, Alimire·Abulimiti , Mairihaba·Kamili , Wang Senlu, Xiang Yang. Analysis of the incidence and influencing factors of household close contacts of pulmonary tuberculosis patients in Kashgar, Xinjiang Uygur Autonomous Region, 2018—2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 390-396. |
[11] | Xia Lan, Liu Shuang, Li Ting, Lu Jia, Wang Danxia, Zhang Linglin. Analysis of screening of close contacts of pathogenic positive pulmonary tuberculosis patients in Sichuan Province from 2018 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 178-182. |
[12] | Shang Xuetian, Pan Liping. Role of tissue kallikrein family in pathogenesis of microorganism infection [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 239-244. |
[13] | Xin Henan, Wang Dakuan, Zhang Bin, Liu Zisen, Duan Weitao, Gao Lei. Prioritizing prevention and enhancing comprehensive interventions to accelerate the end of tuberculosis epidemic—Insights from the implementation of the research projects in Zhongmu County [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1429-1433. |
[14] | Gong Fang, Tan Shouyong, Bao Wanling, Liu Guobiao. Analysis of screening results of close contacts of patients with etiologically negative pulmonary tuberculosis in Yuexiu District,Guangzhou City [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1485-1489. |
[15] | Jiayinati Jingesi, Wang Xinqi, Liu Nianqiang, Wang Senlu, Yipaer Aihaiti, Feng Jianyu, Huang Tao, Kedieryekezi Wufuer. Analysis of treatment completeness and its influencing factors of preventive treatment among 387 latent tuberculosis infection cases [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1496-1503. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||